AI on Drugs: Can Artificial Intelligence Accelerate Drug Development? Evidence from a Large-Scale Examination of Bio-Pharma Firms
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Advances in artificial intelligence (AI) could potentially reduce the complexities and costs in drug discovery. We conceptualize an AI innovation capability that gauges a firm’s ability to develop, manage, and utilize AI resources for innovation. Using patents and job postings to measure AI innovation capability, we find that it can affect a firm’s discovery of new drug-target pairs for preclinical studies. The effect is particularly pronounced for developing new drugs whose mechanism of impact on a disease is known and for drugs at the medium level of chemical novelty. However, AI is less helpful in developing drugs when there is no existing therapy. AI is also less helpful for drugs that are either entirely novel or those that are incremental “followon” drugs. Examining AI skills, a key component of AI innovation capability, we find that the main effect of AI innovation capability comes from employees possessing the combination of AI skills and domain expertise in drug discovery as opposed to employees possessing AI skills only. Having the combination is key because developing and improving AI tools is an iterative process requiring synthesizing inputs from both AI and domain experts during both the development and the operational stages of the tool. Taken together, our study sheds light on both the advantages and the limitations of using AI in drug discovery and how to effectively manage AI resources for drug development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Artificial intelligence capability is increasingly a critical and intangible resource for business performance advancement (Belhadi et al., 2021; Lou and Wu, 2021; Mikalef and Gupta, 2021).”
From The Impact of Artificial Intelligence on Firm Performance: An Application of the Resource-Based View to e-Commerce Firms (2022) · cites this paper as Lou and Wu, 2021
Citations
Cites
Firm Resources and Sustained Competitive Advantage
Barney, J. (1991) · Journal of Management · doi:10.1177/014920639101700108 · Cited by 48,334 · cited 2×
“Lastly, AI-enabled intangibles, including firm practices and knowledge assets that can empower and foster the use of AI, are key drivers for improving firm performance and competitiveness (Barney 1991; Teece 1998).”
Squeeze-and-Excitation Networks
Hu, J., Shen, L., & Sun, G. (2018) · 2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2018.00745 · Cited by 35,667
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241 · cited 3×
“…the Propensity Score Matching (PSM) and Coarsened Exact Matching (CEM) method to match AI and non-AI firms based on the firm characteristics including financial ownership status, firm age, total number of employees and R&D expenses (Blackwell et al. 2009; Ho et al. 2007; Rosenbaum and Rubin 1983).”
Delving Deep into Rectifiers: Surpassing Human-Level Performance on ImageNet Classification
He, K., Zhang, X., Ren, S., & Sun, J. (2015) · 2015 IEEE International Conference on Computer Vision (ICCV) · doi:10.1109/iccv.2015.123 · Cited by 19,741 · cited 1×
“Through many examples of input-output pairs, supervised learning (an area of machine learning) can accurately uncover linkages and make better and faster predictions than humans can in many areas (He et al. 2015; Hu et al. 2018).”
Endogenous Technological Change
Romer, P. M. (1990) · Journal of Political Economy · doi:10.1086/261725 · Cited by 17,711
Squeeze-and-Excitation Networks
Hu, J., Shen, L., Albanie, S., Sun, G., & Wu, E. (2020) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2019.2913372 · Cited by 12,157
The resource-based theory of competitive advantage: Implications for strategy formulation
Grant, R. M. (1991) · California Management Review · doi:10.2307/41166664 · Cited by 9,699 · cited 2×
“…use, and manage AI resources in combination or co-present with other resources and capabilities to effectively conduct scientific discovery and R&D. Grant (1991) suggests that firms can leverage three types of resources to create competitive advantage: tangible resources, personnel-based…”
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 2×
“We also use the free text in the DrugBank database that contains comprehensive information about how each drug works (Wishart et al. 2018; Wishart et al. 2008) to ascertain the drug mechanism.2”
Weininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436 · cited 1×
“Our drug data provide the simplified molecular-input line-entry system (SMILES) code, which is a chemical notation language mainly designed for digital processing (Weininger 1988).”
Bharadwaj, A. S. (2000) · MIS Quarterly · doi:10.2307/3250983 · Cited by 5,042 · cited 5×
“AI Innovation Capability and the Resource-based View of the Firm Firms have developed IT capabilities to gain competitive advantage (Bharadwaj 2000; Santhanam and Hartono 2003).”
InfluentialMatching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference
Ho, D. E., Imai, K., King, G., & Stuart, E. A. (2007) · Political Analysis · doi:10.1093/pan/mpl013 · Cited by 4,205 · cited 3×
“…the Propensity Score Matching (PSM) and Coarsened Exact Matching (CEM) method to match AI and non-AI firms based on the firm characteristics including financial ownership status, firm age, total number of employees and R&D expenses (Blackwell et al. 2009; Ho et al. 2007; Rosenbaum and Rubin 1983).”
Appropriating the Returns from Industrial Research and Development
Levin, R. C., Klevorick, A. K., Nelson, R. R., Winter, S. G., Gilbert, R., & Griliches, Z. (1987) · Brookings Papers on Economic Activity · doi:10.2307/2534454 · Cited by 3,772 · cited 2×
“New drugs are typically patented (Abrams and Sampat 2017; Hemphill and Sampat 2011), because patents are the most effective way to prevent imitations and substitutions (Cohen et al. 2000; Levin et al. 1987).”
“Sticky Information” and the Locus of Problem Solving: Implications for Innovation
von Hippel, E. (1994) · Management Science · doi:10.1287/mnsc.40.4.429 · Cited by 3,718 · cited 1×
“Inferences based on limited data may depend heavily on tacit knowledge that is inherently costly to collect and transfer, and therefore can be difficult to digitize for AI consumption (Nonaka and Von Krogh 2009; Von Hippel 1994).”
The NBER Patent Citation Data File: Lessons, Insights and Methodological Tools
Hall, B., Jaffe, A., & Trajtenberg, M. (2001) · National Bureau of Economic Research · doi:10.3386/w8498 · Cited by 3,507
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 2×
“AI and Drug Discovery Developing drugs is perhaps one of the most expensive and riskiest processes in the world, costing over $2 billion for a typical drug (DiMasi et al. 2016).”
Market value and patent citationsPreprint
Hall, B. H., Jaffe, A. B., & Trajtenberg, M. (2005) · RePEc: Research Papers in Economics · Cited by 3,341
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228 · cited 1×
“The breadth of the search area ranges from genetics to protein synthesis, from biological and chemical synthetic processes to drug mechanisms (Dougherty and Dunne 2012; Vamathevan et al. 2019).”
Cohen, W., Nelson, R., & Walsh, J. (2000) · National Bureau of Economic Research · doi:10.3386/w7552 · Cited by 3,025 · cited 2×
“New drugs are typically patented (Abrams and Sampat 2017; Hemphill and Sampat 2011), because patents are the most effective way to prevent imitations and substitutions (Cohen et al. 2000; Levin et al. 1987).”
Reengineering Work: Don’t Automate, Obliterate
Hammer, M. M. (1990) · Cited by 2,908
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 2×
“We also use the free text in the DrugBank database that contains comprehensive information about how each drug works (Wishart et al. 2018; Wishart et al. 2008) to ascertain the drug mechanism.2”
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Capturing Value from Knowledge Assets: The New Economy, Markets for Know-How, and Intangible Assets
Teece, D. J. (1998) · California Management Review · doi:10.2307/41165943 · Cited by 2,617 · cited 1×
“Lastly, AI-enabled intangibles, including firm practices and knowledge assets that can empower and foster the use of AI, are key drivers for improving firm performance and competitiveness (Barney 1991; Teece 1998).”
A Deep Learning Approach to Antibiotic Discovery
Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.021 · Cited by 2,463
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“Accordingly, it is hard to find new drugs, especially those that differ substantially from existing drugs and that provide big improvements (Krieger et al. 2018; Rotman 2019; Scannell et al. 2012).”
Nonaka, I., & von Krogh, G. (2009) · Organization Science · doi:10.1287/orsc.1080.0412 · Cited by 1,939
Cem: Coarsened Exact Matching in Stata
Blackwell, M., Iacus, S., King, G., & Porro, G. (2009) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0900900402 · Cited by 1,689 · cited 3×
“…the Propensity Score Matching (PSM) and Coarsened Exact Matching (CEM) method to match AI and non-AI firms based on the firm characteristics including financial ownership status, firm age, total number of employees and R&D expenses (Blackwell et al. 2009; Ho et al. 2007; Rosenbaum and Rubin 1983).”
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · cited 1×
“…Medicine uncovered and experimentally tested six new compounds that can inhibit discoidin domain receptor 1 (DDR1), a tyrosine kinase target implicated in fibrosis and other diseases, because those well-known DDR1 and common kinase inhibitors are already well-documented (Zhavoronkov et al. 2019).”
The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine
Tu, Y. (2011) · Nature Medicine · doi:10.1038/nm.2471 · Cited by 1,392 · cited 2×
“Dr. Youyou Tu, the inventor of artemisinin, combined her clinical experience with the ancient text to create a paradigm shift in antimalarial drug development (Tu 2011).”
THIRTY YEARS OF GRAPH MATCHING IN PATTERN RECOGNITION
CONTE, D., FOGGIA, P., SANSONE, C., & VENTO, M. (2004) · International Journal of Pattern Recognition and Artificial Intelligence · doi:10.1142/s0218001404003228 · Cited by 1,370 · cited 1×
“Although many algorithms can compute MCS in general graphs (Conte et al. 2004), they can’t be applied to the study of chemical structures that tend to be represented as small and sparse graphs.”
Reconceptualizing System Usage: An Approach and Empirical Test
Burton-Jones, A., & Straub, D. W. (2006) · Information Systems Research · doi:10.1287/isre.1060.0096 · Cited by 1,040
Issues in Linking Information Technology Capability to Firm Performance1
Santhanam, R., & Hartono, E. (2003) · MIS Quarterly · doi:10.2307/30036521 · Cited by 1,026 · cited 2×
“AI Innovation Capability and the Resource-based View of the Firm Firms have developed IT capabilities to gain competitive advantage (Bharadwaj 2000; Santhanam and Hartono 2003).”
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
The Productivity J-Curve: How Intangibles Complement General Purpose Technologies
Brynjolfsson, E., Rock, D., & Syverson, C. (2021) · American Economic Journal: Macroeconomics · doi:10.1257/mac.20180386 · Cited by 1,003 · cited 2×
“This multi-dimensional measure contrasts with efforts in a burgeoning area of research on AI productivity that primarily tabulates either number of employees or dollar investments to measure AI investment or use (Brynjolfsson et al. 2018; Dixon et al. 2021).”
Aral, S., & Weill, P. (2007) · Organization Science · doi:10.1287/orsc.1070.0306 · Cited by 945 · cited 1×
“This can in turn hurt firms’ long-term competitiveness (Aral and Weill 2007).”
Does Going Public Affect Innovation?
BERNSTEIN, S. (2015) · The Journal of Finance · doi:10.1111/jofi.12275 · Cited by 842 · cited 1×
“Because entrepreneurial exits have been shown to affect organizational innovation outcomes (Bernstein 2015), we control for a firm’s financial ownership status over years (a dummy variable indicating whether it is publicly held).”
Kearns, G. S., & Sabherwal, R. (2006) · Journal of Management Information Systems · doi:10.2753/mis0742-1222230306 · Cited by 573 · cited 1×
“Although the IT alignment literature also shows that the effective use of IT requires the combination of IT- and business-related knowledge (Bassellier and Benbasat 2004; Kearns and Sabherwal 2006), it is limited to the upfront development of the tool (Hammer 1990).”
Artificial intelligence: the next digital frontier?
Bughin, J., Hazan, E., Ramaswamy, S., Chui, M., Allas, T., Dahlström, P., Henke, N., & Trench, M. (2017) · Cited by 569
How artificial intelligence is changing drug discovery
Fleming, N. (2018) · Nature · doi:10.1038/d41586-018-05267-x · Cited by 546 · cited 2×
“Empirical Strategy and Identification The data used for our primary analysis cover the years between 2010 and 2019, which capture the period of rapid advances in AI technologies (Fleming 2018).”
The Impact of Artificial Intelligence on the Labor Market
Webb, M. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3482150 · Cited by 531 · cited 1×
“AI-related Patents We use patents to capture the ability of a firm to either innovate AI technology itself directly or use AI to innovate generally (Webb 2019).”
Bassellier, G., & Benbasat, I. (2004) · MIS Quarterly · doi:10.2307/25148659 · Cited by 515 · cited 1×
“Although the IT alignment literature also shows that the effective use of IT requires the combination of IT- and business-related knowledge (Bassellier and Benbasat 2004; Kearns and Sabherwal 2006), it is limited to the upfront development of the tool (Hammer 1990).”
Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Yao, W., et al. (2020) · arXiv · doi:10.48550/arxiv.2004.10177 · Cited by 511
ChemMine tools: an online service for analyzing and clustering small molecules
Backman, T. W. H., Cao, Y., & Girke, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr320 · Cited by 504 · cited 2×
“Using methods suggested in recent research literature on chemical informatics (Backman et al. 2011; Cao et al. 2008), we measure novelty by assessing the”
Hess, A. M., & Rothaermel, F. T. (2011) · Strategic Management Journal · doi:10.1002/smj.916 · Cited by 492 · cited 3×
“investigational drug database from Clarivate Analytics (Hess and Rothaermel 2011; Kapoor and Klueter 2015; Krieger et al. 2018).”
Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity
Kleis, L., Chwelos, P., Ramirez, R. V., & Cockburn, I. (2012) · Information Systems Research · doi:10.1287/isre.1100.0338 · Cited by 479 · cited 1×
“Such combinations are often valuable, rare, difficult to imitate, and nonsubstitutable, allowing firms to differentiate themselves, improve R&D productivity, and outperform competitors (Bardhan et al. 2013; Joshi et al. 2010; Kleis et al. 2012).”
The Impact of Artificial Intelligence on Innovation
Cockburn, I., Henderson, R., & Stern, S. (2018) · National Bureau of Economic Research · doi:10.3386/w24449 · Cited by 478 · cited 2×
“We also distinguish machine learning from other types of AI investments (Cockburn et al. 2018; WIPO 2019).”
The Robot Revolution: Managerial and Employment Consequences for Firms
Dixon, J., Hong, B., & Wu, L. (2021) · Management Science · doi:10.1287/mnsc.2020.3812 · Cited by 463 · cited 1×
“This multi-dimensional measure contrasts with efforts in a burgeoning area of research on AI productivity that primarily tabulates either number of employees or dollar investments to measure AI investment or use (Brynjolfsson et al. 2018; Dixon et al. 2021).”
Self-citationThe demand for AI skills in the labor market
Alekseeva, L., Azar, J., Giné, M., Samila, S., & Taska, B. (2021) · Labour Economics · doi:10.1016/j.labeco.2021.102002 · Cited by 414
Approaches to Measure Chemical Similarity – a Review
Nikolova, N., & Jaworska, J. (2003) · QSAR & Combinatorial Science · doi:10.1002/qsar.200330831 · Cited by 399
Changing the Competitive Landscape: Continuous Innovation Through IT-Enabled Knowledge Capabilities
Joshi, K. D., Chi, L., Datta, A., & Han, S. (2010) · Information Systems Research · doi:10.1287/isre.1100.0298 · Cited by 387 · cited 1×
“Such combinations are often valuable, rare, difficult to imitate, and nonsubstitutable, allowing firms to differentiate themselves, improve R&D productivity, and outperform competitors (Bardhan et al. 2013; Joshi et al. 2010; Kleis et al. 2012).”
The Value of Patents as Indicators of Inventive Activity
Griliches, Z., Pakes, A., & Hall, B. (1986) · National Bureau of Economic Research · doi:10.3386/w2083 · Cited by 377
Data Analytics, Innovation, and Firm Productivity
Wu, L., Hitt, L., & Lou, B. (2020) · Management Science · doi:10.1287/mnsc.2018.3281 · Cited by 368 · cited 6×
“However, novel drugs that differ radically from existing treatments have almost no precedents, and machine learning is ill-suited to support discovering them (Wu et al. 2020).”
InfluentialSelf-citationThe Productivity of Information Technology Investments: New Evidence from IT Labor Data
Tambe, P., & Hitt, L. M. (2012) · Information Systems Research · doi:10.1287/isre.1110.0398 · Cited by 294 · cited 4×
“Third, we note that the job posting data are not the same as the employment data (Tambe and Hitt 2012) and our study suffers from the limitation that the data do not fully represent the human capital in a firm.”
InfluentialThe Manufacturing Sector Master File: 1959-1987
Hall, B. H. (1990) · National Bureau of Economic Research · doi:10.3386/w3366 · Cited by 287 · cited 5×
“Thus, we can measure a firm’s general investment in patent inventions using the accumulated stock of patent applications by the firm with an annual depreciation rate of 15% (Hall 1990; Hall et al. 2005).6”
InfluentialTrends in clinical success rates
Smietana, K., Siatkowski, M., & Møller, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.85 · Cited by 277 · cited 2×
“About 90% of potential drugs fail to attain FDA approval (Smietana et al. 2016).”
Data Analytics Supports Decentralized Innovation
Wu, L., Lou, B., & Hitt, L. (2019) · Management Science · doi:10.1287/mnsc.2019.3344 · Cited by 229 · cited 1×
“We also use the job title classification from O*NET to identify AI-related positions, similar to how IT and analytics labor are distinguished from other employees in earlier work (Tambe and Hitt 2012; Wu et al. 2019).”
Self-citationDigital science and knowledge boundaries in complex innovation
Dougherty, D., & Dunne, D. D. (2012) · Organization Science · doi:10.1287/orsc.1110.0700 · Cited by 215 · cited 4×
“2 Introduction The drug discovery process is extremely complex (Dougherty and Dunne 2012).”
InfluentialA maximum common substructure-based algorithm for searching and predicting drug-like compounds
Cao, Y., Jiang, T., & Girke, T. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn186 · Cited by 210 · cited 5×
“…drugs based on their known chemical structures.3 Using methods suggested in recent research literature on chemical informatics (Backman et al. 2011; Cao et al. 2008), we measure novelty by assessing the deviation of the chemical structure of a drug candidate from the structures of all prior drugs.”
InfluentialArtificial Intelligence, Economics, and Industrial Organization
Varian, H. (2018) · National Bureau of Economic Research · doi:10.3386/w24839 · Cited by 198 · cited 1×
“First, tangible AI resources may include data, infrastructure and algorithms that are customized for specific scientific discovery (Varian 2018).”
Wawer, M. J., Li, K., Gustafsdottir, S. M., Ljosa, V., Bodycombe, N. E., Marton, M. A., Sokolnicki, K. L., Bray, M.-A., Kemp, M. M., Winchester, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410933111 · Cited by 196 · cited 1×
“Because similarity is highly correlated with chemical novelty, it is widely used to screen for groups of related drugs, and to digitally quantify certain chemical properties without human or animal testing (Wawer et al. 2014).”
Chemoinformatics: What is it and How does it Impact Drug Discovery.
Brown, F. K. (1998) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(08)61100-8 · Cited by 180 · cited 1×
“Yet past generations of IT have had only limited success in discovering new drugs (Brown 1998; Drews This preprint research paper has not been peer reviewed.”
Patents as Surrogates for Inimitable and Non-Substitutable Resources
Markman, G. D., Espina, M. I., & Phan, P. (2004) · Journal of Management · doi:10.1016/j.jm.2003.09.005 · Cited by 175 · cited 3×
“A single patent in the drug space can exert unique influence not only on a product, but also on the technology used for drug discovery itself (Markman et al. 2004).”
InfluentialBardhan, I., Krishnan, V., & Lin, S. (2013) · Information Systems Research · doi:10.1287/isre.2013.0481 · Cited by 173 · cited 1×
“Such combinations are often valuable, rare, difficult to imitate, and nonsubstitutable, allowing firms to differentiate themselves, improve R&D productivity, and outperform competitors (Bardhan et al. 2013; Joshi et al. 2010; Kleis et al. 2012).”
Kapoor, R., & Klueter, T. M. (2014) · Academy of Management Journal · doi:10.5465/amj.2013.0430 · Cited by 167 · cited 3×
“investigational drug database from Clarivate Analytics (Hess and Rothaermel 2011; Kapoor and Klueter 2015; Krieger et al. 2018).”
Mitigating Diminishing Returns to R&D: The Role of Information Technology in Innovation
Ravichandran, T., Han, S., & Mithas, S. (2017) · Information Systems Research · doi:10.1287/isre.2017.0717 · Cited by 162 · cited 2×
“” The combination of several IT-related sources such as IT infrastructure, practices, and employee skills helps firms create IT capability (Bharadwaj 2000; Ravichandran et al. 2017; Tambe and Hitt 2012).”
The high cost of prescription drugs: causes and solutions
Vincent Rajkumar, S. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0338-x · Cited by 160 · cited 1×
“Research has shown that discovering drug candidates aimed at novel therapies that represent big leaps is much harder than discovering therapies offering incremental improvements (“follow-on” drugs) (Rajkumar 2020).”
Artificial Intelligence, Firm Growth, and Industry Concentration
Babina, T., Fedyk, A., He, A. X., & Hodson, J. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3651052 · Cited by 159 · cited 5×
“We measure the total AI skills in firms from job postings, similar to Babina et al. (2020).8 Our job posting data come from a leading analytics company collecting job posts from over 40,000 online job boards and company websites from 2010 to 2019.”
InfluentialKrieger, J., Li, D., & Papanikolaou, D. (2017) · Review of Financial Studies · doi:10.1093/rfs/hhab024 · Cited by 139
When Do Generics Challenge Drug Patents?
Hemphill, C. S., & Sampat, B. N. (2011) · Journal of Empirical Legal Studies · doi:10.1111/j.1740-1461.2011.01235.x · Cited by 118 · cited 2×
“New drugs are typically patented (Abrams and Sampat 2017; Hemphill and Sampat 2011), because patents are the most effective way to prevent imitations and substitutions (Cohen et al. 2000; Levin et al. 1987).”
Data Production Methods for Harmonized Patent Statistics: Patentee Name HarmonizationPreprint
Magerman, T., Looy, B. V., & Song, X. (2006) · SSRN Electronic Journal · doi:10.2139/ssrn.944470 · Cited by 76 · cited 1×
“It also develops a comprehensive approach to standardize the original names of patentees (Magerman et al. 2006).”
Agglomeration of Invention in the Bay Area: Not Just ICT
Forman, C., Goldfarb, A., & Greenstein, S. M. (2016) · American Economic Review · doi:10.1257/aer.p20161018 · Cited by 67 · cited 1×
“10 We also use multiple alternative methods from Forman et al. (2016), such as incorporating electronics-related patents about electrical and semiconductor devices identified from Category 4 in Hall et al. (2001) and searching ITrelated phrases on the titles and abstracts of patents.”
fmcsR: mismatch tolerant maximum common substructure searching in R
Wang, Y., Backman, T. W. H., Horan, K., & Girke, T. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt475 · Cited by 62 · cited 1×
“Our MCS approach eliminates any mismatches and is thus rigidly identified; it provides a lower bound for the pair-wise similarity score (Wang et al. 2013).”
Are All Spillovers Created Equal? A Network Perspective on Information Technology Labor Movements
Wu, L., Jin, F., & Hitt, L. M. (2017) · Management Science · doi:10.1287/mnsc.2017.2778 · Cited by 60 · cited 1×
“Similar to the network-based approaches to construct instrumental variables in Wu et al. (2017), we focus on knowledge flows across firms that serve as a proxy for the cost of accessing AI-related knowledge and reflect the ease of accessing external AIIC from neighboring firms (see Figure 2 for one…”
Self-citationPowerful antibiotics discovered using AI
Marchant, J. (2020) · Nature · doi:10.1038/d41586-020-00018-3 · Cited by 44 · cited 1×
“Not only can Halicin kill many species of antibiotic-resistant bacteria in animal studies, it is also structurally distinct from prior antibiotics (Marchant 2020).”
Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals
Gilchrist, D. S. (2016) · American Economic Journal Applied Economics · doi:10.1257/app.20150373 · Cited by 25 · cited 1×
“Patents can discourage reverse engineering which is much easier than discovering a new drug, thereby preventing theft of intellectual properties (Gilchrist 2016).”
LinearDesign: Efficient Algorithms for Optimized mRNA Sequence DesignPreprint
Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020) · arXiv (Cornell University) · Cited by 14
IT, AI and the Growth of Intangible CapitalPreprint
Tambe, P. B., Hitt, L. M., Rock, D., & Brynjolfsson, E. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3416289 · Cited by 13 · cited 1×
“Patents can also approximate for intangibles and knowledge assets that are critical for future innovation and productivity (Tambe et al. 2019) because they are the culmination of complementary processes, skills, and firm practices.”
Chan, Y. E., & Levallet, N. (2013) · International Conference on Information Systems · Cited by 6
The Knowledge-Incentive Trade-off: Understanding the Organization Design & Innovation Relationship
Eklund, J. C. (2018) · Academy of Management Proceedings · doi:10.5465/ambpp.2018.94 · Cited by 2 · cited 1×
“We account for the transfer of drug patents and their rights using data from the Securities Data Company (SDC) to ensure that drugs in our drug databases are correctly matched to the firms responsible for their original development (Eklund 2018).”
Research works printed but not linked: 11
- Abrams, 2017, What’s the Value of Patent Citations? Evidence from Pharmaceuticals, Working Paper
- Agrawal, 2019, Artificial Intelligence, Scientific Discovery, and Commercial Innovation, Working Paper
- Du Plessis, 2009, Data Production Methods for Harmonized Patent Indicators: Assignee Sector Allocation
- Hitt, 2018, Corporate Data Literacy: Scoring Firms and Firm Performance, IHS Markit White Paper
- Johnson, 1990, Concepts and Applications of Molecular Similarity
- Jones, 2005, Growth and Ideas, 1063
- Marcus, 2019, Rebooting AI: Building Artificial Intelligence We Can Trust
- 2010, Mechanism Matters, Nature Medicine, 16, 347, 10.1038/nm0410-347) · DOI
- Pisano, 2006, Science Business: The Promise, the Reality, and the Future of Biotech
- Raymond, 2019, The AI Index 2019 Annual Report, AI Index Steering Committee, Human-Centered AI Institute, Stanford University
- Trafton, 2020, Artificial Intelligence Yields New Antibiotic, MIT News
Cited by
Managing artificial intelligence
Berente, N., Gu, B., Recker, J., & Santhanam, R. (2021) · MIS Quarterly · doi:10.25300/misq/2021/16274 · Cited by 898
Gama, F., & Magistretti, S. (2025) · Journal of Product Innovation Management · doi:10.1111/jpim.12698 · Cited by 388
The Crowdless Future? Generative AI and Creative Problem-Solving
Boussioux, L., Lane, J. N., Zhang, M., Jacimovic, V., & Lakhani, K. R. (2024) · Organization Science · doi:10.1287/orsc.2023.18430 · Cited by 329
Chen, D., Esperança, J. P., & Wang, S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.884830 · Cited by 198
“Artificial intelligence capability is increasingly a critical and intangible resource for business performance advancement (Belhadi et al., 2021; Lou and Wu, 2021; Mikalef and Gupta, 2021).”
BackgroundManaging with Artificial Intelligence: An Integrative Framework
Hillebrand, L., Raisch, S., & Schad, J. (2025) · Academy of Management Annals · doi:10.5465/annals.2022.0072 · Cited by 254
Metadata
- Authors
- Lou, B., & Wu, L.
- Affiliations
- University of Connecticut (US)
- University of Pennsylvania (US)
- ORCID
- Venue
- MIS Quarterly
- Publisher
- MIS Quarterly
- Published
- 2021-09-01
- Volume
- 45
- Issue
- 3
- Pages
- 1451-1482
- ISSN
- 0276-7783 (ISSN-L)
- 2162-9730
- OpenAlex
- W3200787894
- Cited by
- 177
- References
- 78
- Citations by year
- 2026: 53 · 2025: 58 · 2024: 34 · 2023: 19 · 2022: 10 · 2021: 3
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- MIS Quarterly (publishedVersion)
- Journal of the Association for Information Systems (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Business, Management and Accounting › Strategy and Management › Innovation and Knowledge Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- artificial intelligence, drug discovery, drug development, biopharmaceutical firms, AI competencies, domain knowledge, follow-on drugs, patents, job advertisements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.